Optimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
Jörg Latus, MD
Sayna Norouzi, MD
ASCVD Playbook | Closing the Gaps, One Inning at a Time
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Extra Innings – Sustaining Victory Beyond the First Game
Small Ball Wins Games – Combination Therapy for Goal Attainment
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
Claudia Seikrit, MD
Safety in oHCM Therapy: How and When to Transition Treatment?
Anjali Owens, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Ahmad Masri, MD, MS
Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
Improving Sleep and Mental Health in Patients with CKD-aP
Leonie Kraft, MD
Lucio Manenti, MD, PhD
CKD-aP or Something Else? Decoding the Diagnosis
James Burton, DM, FRCP
Emilio Sanchez, MD, PhD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution